[Echocardiographic evaluation of anti-tumor necrosis factor-alpha therapy with infliximab in patients without cardiac pathologies].

Abstract

In the course of heart failure, plasmatic levels of Tumor Necrosis Factor-alpha (TNF-alpha) are high and are related to prognosis and mortality. Infliximab, a recombinant chimeric antibody anti-TNF-alpha, was used in heart failure with disappointing results, similar to those obtained with other biological drugs.The aim of this study was the echocardiographic evaluation of infliximab infusion in nine patients without cardiac pathologies. The findings demonstrate a reduction of sistolic function and a modification of diastolic function after infliximab infusion in patients without cardiopathy. This study confirms the protective role played by TNFalpha on the myocardium, as suggested by previous experimental studies.

Statistics

0200400201220132014201520162017
Citations per Year

159 Citations

Semantic Scholar estimates that this publication has 159 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Bragagni2010EchocardiographicEO, title={[Echocardiographic evaluation of anti-tumor necrosis factor-alpha therapy with infliximab in patients without cardiac pathologies].}, author={Gianpaolo Bragagni and Federico Lari and Gaetano Magenta and Raffaele Brogna and Giorgio Zoli}, journal={Recenti progressi in medicina}, year={2010}, volume={101 7-8}, pages={289-92} }